Site-specific drug delivery in the gastrointestinal tract

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 6, 2000, Pages 557-620

  Wilding, I ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Drug delivery; Gamma scintigraphy; Gastrointestinal tract; Targeting; Technology

Indexed keywords

ATROPINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; CALCIUM PECTINATE; CARBOMER; CHITIN; ERYTHROMYCIN; EUDRAGIT; LECTIN; MANNITOL; MESALAZINE; METFORMIN; METOCLOPRAMIDE; MICROSPHERE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OLEIC ACID; OLSALAZINE; PECTIN; POLYCARBOPHIL; POLYMER; POLYURETHAN; PRODRUG; PROPANTHELINE BROMIDE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG RESPONSE; DRUG TARGETING; ENTERIC COATED TABLET; ESOPHAGUS; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HUMAN; NONHUMAN; PILL; REVIEW; STOMACH EMPTYING; STOMACH PH; TABLET; ULCERATIVE COLITIS;

EID: 0034510598     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i6.10     Document Type: Review

References (336)

1. Formulations on trial
2. In vivo behavior of dosage forms: Application of gamma scintigraphy to non-enteral routes of administration
3. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms
4. The importance of gamma scintigraphy in pharmaceutical development
5. The role of gamma scintigraphy in oral drug delivery
6. Pill-induced esophageal injury: Case reports and a review of the medical literature
7. Effect of posture and drink volume on the swallowing of capsules
8. Non-steroidal anti-inflammatory drugs and benign esophageal stricture
9. Drug formulation and esophageal injury
10. Esophageal transit of tablets and capsules
11. Esophageal transit of six commonly used tablets and capsules
12. Factors influencing the transit of a gelatin capsule in the esophagus
13. The prejudgment of the esophageal transfer of tablets and capsules
14. Development of a method for study of the tendency of drug products to adhere to the esophagus
15. Adherence of various oral dosage forms to the esophagus
16. Evaluation of esophageal transit and disintegration properties of a rapidly disintegrating tablet using gamma scintigraphy
17. Effect of surface coating of tablets on esophageal transit
18. Movement of food through the alimentary tract
19. A migrating electric complex of the canine small intestine
20. Migrating electrical spike activity in the fasting human small intestine
21. Gastrointestinal myoelectric activity in conscious guinea pigs
22. Origin and characteristics of migrating myoelectric complex in rabbits
23. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine
24. Human interdigestive motility: Variations in patterns from esophagus to colon
25. Spontaneous and 13 NLE motilin induced interdigestive motor activity of the esophagus, stomach and small intestine in man
26. Patterns of intestinal motility
27. Variability of motility of the ileum and jejunum in healthy humans
28. Gastric emptying of liquids and solids: Roles of proximal and distal stomach
29. Gastric emptying of solid and liquid meals in healthy young subjects
30. Gastric emptying of a physiologic mixed meal solid-liquid meal
31. Gastric emptying rate measurement in man. A double isotope scanning technique for simultaneous study of liquid and solid components of a meal
32. Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility
33. Influence of food and marker length on gastric emptying of indigestible radiopaque markers in healthy humans
34. The stomach and its role in oral drug delivery
35. The volume and energy content of meals as determinants of gastric emptying
36. The slowing of gastric emptying by four strong acids and three weak acids
37. The osmotic control of gastric emptying
38. The osmotic effects of some simple molecules and ions on gastric emptying
39. A relation between the chain length of fatty acids and the slowing of gastric emptying
40. Effect of meal volume and energy density on the gastric emptying of carbohydrates
41. Gender related differences in gastric emptying
42. Changes in gastric emptying rates with age
43. Effects of gender, posture, and age on gastric residence time of an indigestible solid: Pharmaceutical considerations
44. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects
45. Effect of age on gastric emptying of liquid-solid meals in man
46. Age does not alter acetaminophen absorption
47. The association of age with gastric emptying
48. Assessment of small bowel function in the elderly using a modified xylose tolerance test
49. Effect of the menstrual cycle on gastric emptying
50. Influence of the menstrual cycle and of menopause on the gastric emptying rate of solids in female volunteers
51. Influence of gender and menopause on gastric emptying and motility
52. Gastric emptying of solids and liquids in obesity
53. Obesity and weight reduction do not influence gastric emptying and antral motility
54. Effect of body posture on radionuclide measurements of gastric emptying
55. The effect of chili on gastrointestinal transit
56. Effect of prolonged exercise on the passage of a solid meal through the stomach and small intestine
57. Exercise increases solid meal gastric emptying rates in men
58. Effect of exercise on gastric emptying and gastric secretion
59. Smoking delays gastric emptying of solids
60. Cigarette smoking delays gastric emptying of a radiolabeled solid food in healthy smokers
61. Effects of cigarette smoking on solid and liquid intragastric distribution and gastric emptying
62. Effect of cigarette smoking on gastric emptying
63. Effect of stress on the gastric emptying of capsules
64. Effect of mild mental stress on solid-phase gastric emptying in healthy subjects
65. Effect of test meal temperature on the gastric emptying of liquids
66. Effects of meal temperature and volume on the emptying of liquid from the human stomach
67. Drugs, disease and altered gastric emptying
68. Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids
69. Prokinetic agents for lower gastrointestinal motility disorders
70. Pharmacological modification of gastric emptying: Effects of propantheline and metoclopramide on paracetamol absorption
71. The effect of pharmacological modification of gastric emptying and mouth-to-caecum transit time on the absorption of sugar probe marker molecules of intestinal permeability in normal man
72. Effect of altered gastric emptying and gastrointestinal motility on Metformin absorption
73. Gastric emptying of solids in man
74. Size of liver particles emptied from the human stomach
75. Canine gastric emptying of solids and liquids
76. Motility of the stomach and gastroduodenal junction
77. Evaluation of the gastrointestinal transit of pharmaceutical dosage forms using the technique of gamma scintigraphy
78. Investigating the gastrointestinal transit of controlled release minimatrices using gamma scintigraphy
79. Comparative study of gastric emptying of digestible and non-digestible solids in normal man and duodenal ulcer patients
80. Gastrointestinal transit of non-disintegrating tablets in fed subjects
81. Gastric emptying of large single-unit dosage forms
82. Effect of distal antrectomy on gastric emptying of liquids and solids
83. Direct measurement of pyloric diameter and tone in man and their response to cholecystokinin
84. The effect of food on the gastrointestinal transit of pellets and an osmotic device (Osmet)
85. Is there a "cut-off" size per se for gastric emptying of tablets in man?
86. A comparative study of the gastrointestinal transit of a pellet and tablet formulation
87. Estimation of gastric residence time of the heidelberg capsule in humans: Effect of varying food composition
88. The effect of tablet size on the gastric emptying of non-disintegrating tablets
89. Gastric emptying of enteric-coated tablets
90. Physiological factors and controlled release dosage forms
91. Gastric emptying of wholemeal and white bread
92. Models of gastric emptying
93. Do pellet formulations empty from the stomach with food?
94. The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations
95. The influence of food on the gastric emptying of multiparticulate dosage forms
96. Gross morphology of the gastrointestinal tract
97. Small intestinal physiology and pathophysiology
98. The movements and innervation of the small intestine
99. Peristalsis, segmentation, and the myenteric reflex
100. Small bowel
101. The small intestine and colon: Scintigraphic quantitation of motility in health and disease
102. Relationship of motility to flow of contents in the human small intestine
103. The human MMC moves slightly slower by night
104. Circadian variation in the propagation velocity of the migrating myoelectric complex
105. The interdigestive myoelectric complex of the stomach and small bowel of dogs
106. Cyclic motor activity: Migrating motor complex
107. Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach?
108. Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns
109. Human migrating myoelectric complex in relation to gastrointestinal transit of a meal
110. Intestinal transit of solid and liquid components of a meal in health
111. Differential transit of liquids and solid residue through the human ileum
112. Small bowel transit time of food in man: Measurement, regulation and possible importance
113. The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man
114. Psychological stress and the passage of a standard meal through the stomach and small intestine in man
115. Effects of acute psychologic stress on small intestine motility in health and the irritable bowel syndrome
116. Sustained mental stress alters human jejunal motor activity
117. Effects of different types of stress and prokinetic drugs on the control of fasting motor complexes in humans
118. Gastrointestinal transit: The effect of the menstrual cycle
119. Gastrointestinal transit time in human pregnancy: Prolongation in the second and third trimesters followed by postpartum normalization
120. Exercise and small intestinal transit
121. Scintigraphic determination of the effect of metoclopramide and morphine on small intestinal transit time
122. A comparison of metoclopramide and trimebutine on small bowel motility in humans
123. Transit of pharmaceutical dosage forms through the small intestine
124. The influence of density on the gastrointestinal transit of pellets
125. Gastrointestinal transit of non-disintegrating solid formulations in humans
126. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time
127. The effects of pharmaceutical excipients on small intestinal transit
128. The effect of different concentrations of mannitol in solution on small intestinal transit: Implications for drug absorption
129. The effect of mannitol on the oral bioavailability of cimetidine
130. The influence of polyethylene glycol 400 on small intestinal transit and Ranitidine absorption
131. Small intestinal transit
132. Further characterization of the "ileal brake" reflex in man - Effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY
133. Characteristics of lipid substances activating the ileal brake in the rat
134. The effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans
135. The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations
136. Progress report: Motility of the ileocolonic region
137. Endoscopy of the ileocecal area
138. Distinctive patterns of interdigestive motility at the canine ileocolonic junction
139. Motility of the terminal ileum and ileocecal sphincter in healthy humans
140. Contractile patterns and transit of fluid in canine terminal ileum
141. Capacity of the human colon to absorb fluid
142. The contribution of the colon to electrolyte and water conservation in man
143. Emptying of terminal ileum in intact humans
144. Small intestinal motili and transit in disease
145. Human gastric emptying and colonic filling of solids characterized by a new method
146. Colonic transit of different sized tablets in healthy subjects
147. Gastric emptying and small and large bowel transit of nondisintegrating tablets in fasted subjects
148. Anatomy and physiology of the colon, rectum, and anus
149. Bacterial fermentation of carbohydrates within the gastrointestinal tract
150. The gut microflora and its significance
151. The control and consequences of bacterial fermentation in the human colon
152. The relationships between colonic motility and transport
153. Colonic motor activity and bowel function, Part I. Normal movement of contents
154. Colon
155. Human colonic motility
156. Twenty-four hour colonic motility patterns in normal ambulant subjects
157. The physiology of colonic motor activity
158. Association between postprandial changes in colonic intraluminal pressure and transit
159. The effect of meal composition on the gastrocolonic response: Implications for drug delivery to the colon
160. Colonic motor activity and bowel function. Part II, Distribution and incidence of motor activity at rest and after food and carbachol
161. Effect of eating and gastrointestinal hormones on human colonic myoelectrical and motor activity
162. Comparison of intraluminal and intravenous mediators of colonic response to eating
163. Effect of dietary components on gastrocolonic response
164. The normal range and a simple diagram for recording whole gut transit time
165. A new method for studying gut transit times using radio-opaque markers
166. Colonic transit and drug delivery
167. Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea
168. Fibre and bowel transit times
169. The effect of wheat bran on intestinal transit
170. The effect of fiber on gastrointestinal transit times in vegetarians and omnivores
171. A review of research on effects of fiber intake on man
172. Mass peristalsis in the human colon after contact with oxyphenisatin
173. Decreased fluid tolerance accelerated transit and abnormal motility of the human colon induced by oleic acid
174. Intestinal streaming patterns in cholerrhoeic enteropathy and diverticular disease
175. Unprepared colon does not discriminate between solids and liquids
176. Medical and dietary management
177. Drug delivery to the proximal colon
178. The intestinal transit of capsules and pellets
179. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting
180. An oral preparation to release drugs in the human colon
181. Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules
182. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease
183. Measurement of gastrointestinal pH profiles in normal ambulant human subjects
184. Very low intraluminal colonic pH in patients with active ulcerative colitis
185. Gastrointestinal pH profiles in ulcerative colitis
186. Gastrointestinal transit of small tablets in patients with ulcerative colitis
187. Studies on the mechanism of bowel disturbance in ulcerative colitis
188. Gastrointestinal motility in patients with ulcerative colitis
189. Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis
190. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop
191. Buccal and gastrointestinal drug delivery systems
192. Methods used to develop mucoadhesive drug delivery systems: Bioadhesion in the gastrointestinal tract
193. The effect of polycarbophil on the gastric emptying of pellets
194. Gastrointestinal transit of potential bioadhesive formulations in man: A scintigraphic study
195. Bioadhesive polymers as platforms for oral controlled drug delivery, III. Oral delivery of chlorthiazide using a bioadhesive polymer
196. The use of bioadhesives in targeted delivery within the gastrointestinal tract
197. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded aginate and poly(fumaric-co-sebacic anhydride) mirospheres
198. Enhanced peptide absorption by the mucoadhesive polymers polycarbophil and chitosan
199. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
200. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug
201. Vancomycin and insulin used as models for oral delivery of peptides
202. The potential of lectins for oral drug delivery: In vitro and in vivo uptake of tomato lectin
203. Lectins
204. Tomato lectin resists digestion in the mammalian alimentary canal and binds to intestinal villi without deleterious effects
205. Transport of proteins through the membranes of the adult gastrointestinal tract - A potential for drug delivery?
206. Lectin-mediated bioadhesion: Proteolytic stability and binding-characteristics of wheat germ agglutinin and Solanum tuberosum lectin on Caco-2, HT-29, and human colonocytes
207. The potential of fimbrial proteins for delaying intestinal transit of drug delivery systems
208. Investigation of minor components of Escherichia coli Type 1 fimbriae: Protein chemical and immunological aspects
209. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine
210. Relative bioavailability of olsalazine from tablets and capsules: A drug targeted for local effect in the colon
211. Influence of olsalazine on gastrointestinal transit in ulcerative colitis
212. Studies of two novel sulfasalazine analogs, ipsalazide and basalazide
213. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine
214. Drug glycosides in oral colon-specific drug delivery
215. Design and synthesis of colon-specific pro-antedrugs, 20-glucopyranosyloxy methylprednisolonates, for oral treatment of ulcerative colitis and their metabolism
216. Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig
217. In vitro Evaluation of Dexamethasone-β-D-Glucuronide for Colon-Specific Drug Delivery
218. Macromolecular prodrugs. XV. Colon-targeted delivery - Bioavailability of naproxen from orally administered dextrannaproxen ester prodrugs varying in molecular size in the pig
219. Enteric coatings and delayed release
220. Gastric residence times of enteric coated dosage forms
221. The evaluation of an enteric-coated naproxen tablet formulation using gamma scintigraphy
222. In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy
223. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms
224. Review of NSAID-induced upper gastrointestinal morbidity and mortality
225. A review of upper gastrointestinal effects of the newer NSAIDs
226. Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects
227. In vitro and in vivo evaluation of pectin for colonic drug delivery
228. Some biological issues in oral, controlled drug delivery
229. Absorption of delayed-release prednisolone in ulcerative colitis and Crohn's disease
230. Disposition of Mesalazine from Mesalazine-Delivering Drugs in Patients with Inflammatory Bowel Disease, with and without Diarrhea
231. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet
232. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease
233. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis
234. pH-Profile and regional transit times of the normal gut measured by a radiotelemetry device
235. A Scintigraphic Study to Evaluate What Happens to Pentasa® and Asacol® in the Human Gut
236. Colonic Drug Delivery
237. Coating of oral beclomethasone diproprionate capsules with cellulose acetate phthalate enhances delivery of topically active anti-inflammatory drug to the terminal ileum
238. The in vivo behavior of a colonic delivery system: A pilot study in man
239. Development and Human in vivo Evaluation of a Colonic Drug Delivery System
240. Radionuclides in drug formulation studies
241. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation
242. "The Time Clock® system: A new oral dosage form for fast and complete release of drug after a predetermined lag time
243. Enteric Coated Timed Release Systems for Colonic Targeting
244. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIMECLOCK®" system)
245. Design and evaluation of a new capsule-type dosage form for colon-targeted delivery of drugs
246. Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers
247. Gastrointestinal Transit of a Putative Bioadhesive Matrix Tablet: Comparison of Canine and Human Data
248. The effect of food on the in vivo behavior of enteric coated starch capsules
249. Oral colon-specific drug delivery: Design strategies
250. Starch capsules: An alternative system for oral drug delivery
251. Development of a multiple unit drug delivery system for positioned release in the gastrointestinal tract
252. Fermentation of nonstarch polysaccharides in mixed diets and single fibre sources: Comparative studies in human subjects and in vitro
253. Measurement of the mean transit time of dietary residue through the human gut
254. Short-chain fatty acids in human large intestine, portal, hepatic, and venous blood
255. The colonic flora, fermentation, and large bowel digestive function
256. Normal indigenous intestinal flora
257. Targeting drugs to the colon: Delivery systems for oral administration
258. Approaches and opportunities in colon-specific drug delivery
259. Oral colon-specific drug delivery using amylose-based film coatings
260. Colon targeting of ATL-2502 (prednisolone sodium metasulphobenzoate) using COLAL™ coating
261. Chemically modified polysaccharides for enzymatically controlled oral drug delivery
262. Properties of fractionated chondroitin sulphate from ox nasal septa
263. Energy sources of major intestinal fermentative anærobes
264. Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery
265. Colonic drug delivery: Enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content
266. Enzymatic cleavage of disaccharide side groups in insoluble synthetic polymers: A new method for specific delivery of drugs to the colon
267. An evaluation of pectin as a carrier for drug targeting to the colon
268. Studies on pectin formulations for colonic drug deliver
269. Pectin/ethylcellulose film coating formulations for chronic drug delivery
270. Calcium pectate: A potential colon-specific drug delivery carrier
271. In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier
272. The use of scintigraphy to provide "proof of concept" data for novel polysaccharide preparations designed for colonic drug delivery
273. The degradation of guar gum by a fecal incubation system
274. Colonic delivery of Dexamethasone: A pharmacoscintigraphic clinical evaluation
275. Drug delivery to the colon: Polymer susceptibility to degradation by colon contents
276. Methacrylate-galactomannan coating for colon-specific drug delivery
277. Human gastrointestinal transit study of a novel colon delivery system (CODES) using gamma scintigraphy
278. Pharmacoscintigraphic evaluation of a colon-specific delivery system in healthy volunteers
279. Coated dosage forms for colon-specific drug delivery
280. Role of gut bacterial flora in nutrition and health: A review of recent advances in bacteriological techniques, metabolism, and factors affecting flora composition
281. Bioadhesive water-soluble polymeric drug carriers for site-specific oral drug delivery. Synthesis, characterization, and release of 5-aminosalicylic acid by Streptococcus faecium in vitro
282. Metabolism of foreign compounds by gastrointestinal microorganisms
283. Redox potential measurement in the gastrointestinal tract in man
284. The evaluation of microbially activated colonic drug delivery systems
285. A new approach to the oral administration of insulin and other peptide drugs
286. Oral insulin in diabetic dogs
287. Azo polymers for colon-specific drug delivery
288. Degradation of azo-containing polyurethane by the action of intestinal flora: Its mechanism and application as a drag delivery system
289. Development of an azopolymer based colonic release capsule for delivering proteins/macromolecules
290. Cysteine conjugate β-lyase in the gastrointestinal bacterium Fusobacterium necrophorum
291. Hydrogels for site-specific oral drug delivery: Synthesis and characterization
292. Polymers for colon-specific drug delivery
293. Composition providing selective release of an active ingredient
294. Oral delayed immediate release formulation and method of preparation therefor
295. Site-specific controlled release dosage formulation for mesalamine
296. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery
297. A new technique for segmental jejunal perfusion in man
298. Other methods in studying colonic drug absorption
299. Absorption of ipsapirone along the human gastrointestinal tract
300. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule
301. Measurement of theophylline absorption from different regions of the gastrointestinal tract using a remote controlled drug delivery device
302. Voraussetzung für die Entwicklung einer sinvollen Retard- und Diuretikakombination
303. Investigation of nifedipine absorption in different regions of the human gastrointestinal tract after simultaneous administration of 13C- and 12C-nifedipine
304. The InteliSite™ capsule: A new easy-to-use approach for assessing regional drug absorption from the gastrointestinal tract
305. Gamma scintigraphic evaluation of the intestinal absorption of stavudine in healthy male volunteers using Intelisite® capsule
306. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis
307. 99mTc-labelled 5-ASA suppositories
308. Colonic motility and enema spreading
309. Enema volume and spreading
310. The application of gamma scintigraphy for the evaluation of the relative spreading of suppository bases in rectal hard gelatin capsules
311. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis
312. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy
313. The effect of food on the gastrointestinal transit and systemic absorption of Naproxen front a novel sustained release formulation
314. Evaluation of an enteric-coated Naproxen pellet formulation
315. Localization of drug release sites from an oral sustained release formulation of 5-ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy
316. Scintigraphic evaluation of colonic delivery systems
317. Pharmacoscintigraphic evaluation of a modified release (Geomatrix®) formulation